Literature DB >> 16528245

Hypertension in renal parenchymal disease: why is it so resistant to treatment?

V M Campese1, N Mitra, D Sandee.   

Abstract

The association between hypertension and chronic renal disease is well known. The pathogenesis of hypertension in patients with chronic kidney disease (CKD) is complex and multifactorial, which may explain why it is resistant to treatment. The traditional paradigm is that hypertension in CKD is due either to an excess of intravascular volume (volume dependent) or to excessive activation of the renin-angiotensin system in relation to the state of sodium/volume balance (renin-dependent hypertension). This review focuses on the importance of less established mechanisms, such as increased activity of the sympathetic nervous system, increased endothelin production, decreased availability of endothelium-derived vasodilators and structural changes of the arteries, renal ischemia, and sleep apnea.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528245     DOI: 10.1038/sj.ki.5000177

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  36 in total

Review 1.  Pathogenesis of essential hypertension: historical paradigms and modern insights.

Authors:  Richard J Johnson; Dan I Feig; Takahiko Nakagawa; L Gabriela Sanchez-Lozada; Bernardo Rodriguez-Iturbe
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

2.  Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy: studies in sympathectomized rats.

Authors:  Robert A Augustyniak; Maria M Picken; David Leonard; Xin J Zhou; Weiguo Zhang; Ronald G Victor
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-06-29       Impact factor: 2.557

3.  Hyperreninemic hypertension following presumed abdominal trauma.

Authors:  Eduardo Pimenta; Richard D Gordon; Nicholas Daunt; Gregory Slater; Michael Stowasser
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

4.  Resistant hypertension and obstructive sleep apnea in the setting of kidney disease.

Authors:  Khaled Abdel-Kader; Sheena Dohar; Nirav Shah; Manisha Jhamb; Steven E Reis; Patrick Strollo; Daniel Buysse; Mark L Unruh
Journal:  J Hypertens       Date:  2012-05       Impact factor: 4.844

Review 5.  Recognition and Management of Resistant Hypertension.

Authors:  Branko Braam; Sandra J Taler; Mahboob Rahman; Jennifer A Fillaus; Barbara A Greco; John P Forman; Efrain Reisin; Debbie L Cohen; Mohammad G Saklayen; S Susan Hedayati
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-28       Impact factor: 8.237

6.  Comparison of high-fat style diet-induced dysregulation of baroreflex control of renal sympathetic nerve activity in intact and ovariectomized female rats: Renal sympathetic nerve activity in high-fat style diet fed intact and ovariectomized female rats.

Authors:  Yamuna Sucedaram; Edward James Johns; Ruby Husain; Munavvar Abdul Sattar; Mohammed Abdulla; Manizheh Khalilpourfarshbafi; Nor Azizan Abdullah
Journal:  Exp Biol Med (Maywood)       Date:  2020-03-25

Review 7.  Signaling mechanisms that link salt retention to hypertension: endogenous ouabain, the Na(+) pump, the Na(+)/Ca(2+) exchanger and TRPC proteins.

Authors:  Mordecai P Blaustein; John M Hamlyn
Journal:  Biochim Biophys Acta       Date:  2010-03-06

8.  Resolution of systemic hypertension after laparoscopic gastric bypass.

Authors:  Marcelo W Hinojosa; J Esteban Varela; Brian R Smith; Fredrick Che; Ninh T Nguyen
Journal:  J Gastrointest Surg       Date:  2008-12-03       Impact factor: 3.452

Review 9.  [Hypertension and the kidney].

Authors:  Katharina Hohenstein; Bruno Watschinger
Journal:  Wien Med Wochenschr       Date:  2008

10.  Prevalence of apparent treatment-resistant hypertension among individuals with CKD.

Authors:  Rikki M Tanner; David A Calhoun; Emmy K Bell; C Barrett Bowling; Orlando M Gutiérrez; Marguerite R Irvin; Daniel T Lackland; Suzanne Oparil; David Warnock; Paul Muntner
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.